News | Radiation Therapy | October 18, 2016

Yale research suggests patients treated at higher-volume facilities were more likely to have improved survival, shorter radiotherapy duration

intensity modulated radiation therapy outcomes, IMRT, head and neck cancers, facility volume, ASTRO 2016

October 18, 2016 — The association between provider case volume and outcomes has long been suggested in cancer care. A Yale Cancer Center team has completed a review of outcomes for patients with locally advanced squamous cell head and neck cancers treated with intensity-modulated radiation therapy (IMRT) and found a distinct association between higher-volume treatment centers and improved overall survival. The findings were presented Sept. 26 at the American Society for Therapeutic Radiology and Oncology (ASTRO) meeting in Boston.

This study used the National Cancer Data Base to analyze 9,817 patients and found that patients treated at higher-volume facilities were more likely to have shorter radiation therapy duration than those at lower volume facilities.

The research team’s findings also revealed there was a 5.7 percent decreased hazard of death per additional 20 patients treated per year per facility. When annual facility case volume was defined based on a threshold of 95 cases/year (90th percentile), there was a 17.5 percent decreased hazard of death for higher-volume versus lower-volume facilities.

“Our findings suggest a strong relationship between higher-volume radiation therapy facilities and improved overall survival for patients treated with IMRT for locally advanced head and neck cancers,” said Henry S. Park, MD, MPH, first author on the study and a chief resident in the Department of Therapeutic Radiology at Yale School of Medicine. “Further investigation should focus on the role of other factors potentially underlying this association, including radiation contouring, education, multidisciplinary communication, and toxicity management.”

For more information: www.astro.org


Related Content

News | Artificial Intelligence

March 28, 2024 — As artificial intelligence (AI) makes its way into cancer care – and into discussions between ...

Time March 28, 2024
arrow
News | Prostate Cancer

March 27, 2024 — A minimally invasive treatment using MRI and transurethral ultrasound instead of surgery or radiation ...

Time March 27, 2024
arrow
Videos | Radiation Oncology

In the conclusion of this 3-part video series on recent advancements in diagnostic radiology, current editorial advisory ...

Time March 19, 2024
arrow
News | Breast Imaging

March 18, 2024 — QT Imaging Holdings, Inc., a medical device company engaged in research, development, and ...

Time March 18, 2024
arrow
Feature | Radiation Oncology | By Christine Book

Appreciating the considerable advances in the clinical application of artificial intelligence (AI) within healthcare ...

Time March 06, 2024
arrow
News | FDA

March 1, 2024 — Varian, a Siemens Healthineers company, announced that it has received 510(k) clearance from the U.S ...

Time March 01, 2024
arrow
News | Breast Imaging

February 22, 2024 — The FAST-Forward randomized trial from the UK found that ultrahypofractionated whole breast ...

Time February 22, 2024
arrow
News | Radiation Oncology

February 22, 2024 — The National Institutes of Health has launched a clinical trials network to evaluate emerging ...

Time February 22, 2024
arrow
News | Radiation Oncology

February 14, 2024 — Accuray Incorporated announced that the team at Quebec’s Montérégie Integrated Cancer Center, part ...

Time February 14, 2024
arrow
News | Radiation Oncology

February 12, 2024 — Radformation, a global pioneer in radiation oncology software solutions, is pleased to announce its ...

Time February 12, 2024
arrow
Subscribe Now